Relative Bioavailability of Dolutegravir (DTG) and Emtricitabine/Tenofovir Alafenamide Fumarate (F/TAF) Administered as Paediatric Tablet Formulations in Healthy Volunteers
Clinical Pharmacokinetics · 2024
DOI: 10.1007/s40262-024-01365-4 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacokinetics, 2024. Verfasst von Lisanne A H Bevers und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy (route 864), Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, The Netherlands. Lisanne.Bevers@…. Hauptthemen laut MEDLINE: Pyridones, Heterocyclic Compounds, 3-Ring, Tenofovir, Emtricitabine. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Gilead UK and Ireland Corporate Contributions.
Abstract (Originalsprache)
BACKGROUND AND OBJECTIVE: Within the UNIVERSAL project (RIA2019PD-2882) we aim to develop a paediatric dolutegravir (DTG)/emtricitabine (FTC or F)/tenofovir alafenamide (TAF) fixed-dose combination. To inform dosing of this study, we undertook a relative bioavailability (RBA) study in healthy volunteers to investigate a potential pharmacokinetic effect when paediatric formulations of DTG and F/TAF are taken together. METHODS: Participants received all of the following treatments as paediatric formulations in randomised order: a single dose of 180/22.5 mg F/TAF; a single dose of 30 mg DTG; a single dose of 180/22.5 mg F/TAF plus 30 mg DTG. Blood concentrations of DTG, FTC, TAF, and tenofovir (TFV) were measured over 48 h post-dose. If the 90% confidence intervals (CIs) of the geometric least squares mean (GLSM) ratios of area under the curve (AUC) and maximum concentration (Cmax) of each compound were within 0.70-1.43, we considered this as no clinically relevant PK interaction. RESULTS: A total of 15 healthy volunteers were included. We did not observe a clinically relevant PK interaction between the paediatric DTG and F/TAF formulations for the compounds DTG, FTC, and TFV. For TAF, the lower boundaries of the 90% CIs of the GLSM ratios of the AUC0-∞ and Cmax fell outside our acceptance criteria of 0.70-1.43. CONCLUSIONS: Although TAF AUC and Cmax 90% CIs fell outside the pre-defined criteria (0.62-1.11 and 0.65-1.01, respectively), no consistent effect on TAF PK was observed, likely due to high inter-subject variability. Moreover, there are several reasons to rely on TFV exposure as being more clinically relevant than TAF exposure. Therefore, we found no clinically relevant interactions in this study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy (route 864), Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, The Netherlands. Lisanne.Bevers@radboudumc.nl.
- Department of Pharmacy (route 864), Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, The Netherlands.
- Clinical Pharmacology, Paediatric Centre of Excellence, Gilead Sciences, Dublin, Ireland.
ORCID-Profile: Lisanne A H Bevers
Förderung
- Gilead UK and Ireland Corporate Contributions
Zitieren
APA
Bevers, L. A. H., Kamphuis, A. E. M., van der Wekken-Pas, L. C. W., Leisegang, R., Burger, D. M., & Colbers, A. (2024). Relative Bioavailability of Dolutegravir (DTG) and Emtricitabine/Tenofovir Alafenamide Fumarate (F/TAF) Administered as Paediatric Tablet Formulations in Healthy Volunteers. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-024-01365-4
Vancouver
Bevers LAH, Kamphuis AEM, van der Wekken-Pas LCW, Leisegang R, Burger DM, Colbers A. Relative Bioavailability of Dolutegravir (DTG) and Emtricitabine/Tenofovir Alafenamide Fumarate (F/TAF) Administered as Paediatric Tablet Formulations in Healthy Volunteers. Clinical Pharmacokinetics. 2024. doi:10.1007/s40262-024-01365-4
BibTeX
@article{Bevers2024,
author = {Bevers, Lisanne A H and Kamphuis, Anne E M and van der Wekken-Pas, L C Wendy and Leisegang, Rory and Burger, David M and Colbers, Angela},
title = {Relative Bioavailability of Dolutegravir (DTG) and Emtricitabine/Tenofovir Alafenamide Fumarate (F/TAF) Administered as Paediatric Tablet Formulations in Healthy Volunteers},
journal = {Clinical Pharmacokinetics},
year = {2024},
doi = {10.1007/s40262-024-01365-4}
}
EUVIMED